Monte Rosa Therapeutics: Clinical Stage, next-generation molecular glue-based targeted protein degradation platform developing small molecule therapeutics that selectively degrade disease-causing proteins. AI-based degron prediction targets the undruggable proteome in both oncology and other disease areas. Extensive preclinical data demonstrating potent anti-tumor activity. Lead asset MRT-2359 targeting degradation of GSPT1 and dosed first patient in 4Q22 in a Phase 1/2 study in patients with MYC-driven solid tumors, including lung cancer.